Wellington Partners

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Seamless Therapeutics is focused on advancing gene editing through an innovative technology platform that reprograms recombinases, a versatile class of enzymes. The company's approach aims to restore health in patients with severe medical conditions safely and precisely. By developing disease-modifying product candidates, Seamless Therapeutics seeks to broaden the therapeutic applications of gene editing, ultimately enhancing treatment options for patients.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Nyra Health is a digital therapy platform founded in 2020 and headquartered in Vienna, Austria. It focuses on addressing personal neurological deficits through an artificial intelligence-driven application. The platform provides evidence-based therapies that can be utilized in clinics or at home, making rehabilitation accessible regardless of time or location. By leveraging advanced technology, Nyra Health aims to empower patients to maximize their rehabilitation potential effectively.

Seamless Therapeutics is focused on advancing gene editing through an innovative technology platform that reprograms recombinases, a versatile class of enzymes. The company's approach aims to restore health in patients with severe medical conditions safely and precisely. By developing disease-modifying product candidates, Seamless Therapeutics seeks to broaden the therapeutic applications of gene editing, ultimately enhancing treatment options for patients.

Nosto provides a commerce experience platform tailored for the global e-commerce industry. Its platform-independent software-as-a-service (SaaS) solution enhances the online shopping experience through real-time personalized product recommendations. Designed for accessibility, Nosto's technology caters to online retailers of all sizes, offering a plug-and-play system that automates marketing activities. This approach significantly boosts conversion rates, customer retention, and overall store revenues. Additionally, Nosto enables retailers to maintain up-to-date product and shopper data, facilitating personalized shopping experiences across multiple devices and touchpoints. Clients can efficiently build, launch, and optimize multi-channel marketing campaigns without the need for extensive resources or back-end integration.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Orcan Energy is the leader in waste heat recovery technology. Orcan Energy GmbH was founded in 2008, as a spin-out from the Technical University of Munich (“TUM”). Orcan’s ePack offers a compact, service-reduced and cost- efficient “plug-and-play” waste heat power generator based on ORC-Technology. Spe- cific patented innovations enable Orcan to popularize the technology on the mass mar- ket. At the beginning of 2013, Orcan gained sponsorships from the Exist-Research- Transfer-Aid of the Federal Government of Germany and additional grants from the “Wissensfabrik” and various resources from the TUM.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Cayaba Care is a maternal health company that offers comprehensive support for medium and high-risk women throughout their pregnancy and postpartum journeys. By combining virtual and in-person services, Cayaba Care provides a multidisciplinary approach led by Maternity Navigators, who are also certified doulas. These navigators work closely with clients to address various needs, including mental health, breastfeeding support, and postpartum follow-up, ensuring successful birth outcomes. The company partners with both commercial and Medicaid plans, utilizing standard and value-based care contracts to enhance the quality of care, improve the overall experience for patients, and achieve significant cost savings. Cayaba Care aims to alleviate the symptoms, pain, and anxiety associated with pregnancy, promoting a healthy and safe experience for expectant mothers.

Sidekick is a patient-centric digital care platform designed to manage and prevent chronic and lifestyle-related conditions. It offers a scalable solution that enhances healthcare by developing digital health products aimed at empowering patients and digitizing healthcare processes. The platform combines an evidence-based clinical approach with elements of behavioral economics and gamification, creating a more engaging healthcare experience. Sidekick's integrated platform supports multi-chronic condition management and personalized care, facilitating connections between users and clinicians while providing valuable data insights. The company collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve health outcomes.

Xepelin is a financial technology company focused on transforming business finance for small and medium-sized enterprises (SMEs) in Latin America. The company offers a range of digital financial services, including short-term and long-term loans, capital credits, and accounts payable financing through an online platform. Xepelin aims to provide SMEs with economic freedom in their financial decisions by allowing clients to personalize services to meet their specific needs. With a team of over 500 employees, Xepelin leverages advanced financial indicators and risk assessments to streamline decision-making processes within the business ecosystem. The company is supported by notable investors, positioning it as a leader in the region's evolving financial landscape.

Union, an all-in-one hospitality engagement platform, leverages industrial grade data intelligence to deliver transformative experiences for the industry’s most popular venues, their guests, and their brand partners.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx Therapeutics has identified several new targets and examined their mechanisms of action. The company's foundation is built upon the principles of cancer immune-checkpoint therapy, which aims to overcome the resistance mechanisms that tumors utilize to evade immune attacks. These resistance mechanisms often involve specific cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Automattic Inc. is a technology company founded in 2005 and headquartered in San Francisco, California. It specializes in developing web-based solutions that enhance online presence and functionality. The company is best known for its flagship product, WordPress.com, which allows users to create and manage websites easily. In addition to WordPress.com, Automattic offers a variety of products including WooCommerce for e-commerce, Jetpack for site performance and security, and other tools designed to support web hosting, security, and enterprise infrastructure. By focusing on open-source content management systems, Automattic aims to democratize publishing and commerce, enabling users to share their stories and content across various platforms, regardless of their background or location. The company serves both non-profit and open-source projects in the United States and internationally.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Advanced Medical Balloons specializes in the development of custom-made balloon components designed for low and very low pressure applications, which significantly enhances catheter design. The company utilizes advanced technology featuring microscopically thin, complex-shaped balloon films made from polyurethane. This innovation allows medical device manufacturers to explore new business models and assess the associated risks and opportunities in the medical technology sector. By focusing on tailored solutions, Advanced Medical Balloons aims to contribute to the advancements in medical devices and improve patient care.

Koa Health B.V., founded in 2018 and based in Amsterdam with additional offices in Barcelona, the United States, and the United Kingdom, develops digital solutions aimed at enhancing mental well-being for employees. The company provides a range of products that are informed by the latest clinical research and technology. Its offerings include the koa foundation application, which supports early symptom management and mild mental health issues, and Mindset, a chat-based platform for private mental health support. Koa Health’s solutions encompass prevention, prediction, and treatment, featuring a library of evidence-based activities designed to address various mental health challenges, such as stress management, sleep improvement, and confidence building. By delivering scalable and affordable care, Koa Health aims to make mental health support accessible and effective for individuals and organizations alike.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

IconOVir Bio is a preclinical-stage biotechnology company focused on developing innovative oncolytic virus therapies for cancer treatment. The company's proprietary platform aims to overcome the limitations associated with first- and second-generation oncolytic viruses, thereby enhancing the therapeutic options available to healthcare professionals. By prioritizing personalized therapy, IconOVir Bio seeks to improve treatment outcomes for cancer patients, positioning itself at the forefront of advancements in oncology.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Koa Health B.V., founded in 2018 and based in Amsterdam with additional offices in Barcelona, the United States, and the United Kingdom, develops digital solutions aimed at enhancing mental well-being for employees. The company provides a range of products that are informed by the latest clinical research and technology. Its offerings include the koa foundation application, which supports early symptom management and mild mental health issues, and Mindset, a chat-based platform for private mental health support. Koa Health’s solutions encompass prevention, prediction, and treatment, featuring a library of evidence-based activities designed to address various mental health challenges, such as stress management, sleep improvement, and confidence building. By delivering scalable and affordable care, Koa Health aims to make mental health support accessible and effective for individuals and organizations alike.

Sidekick is a patient-centric digital care platform designed to manage and prevent chronic and lifestyle-related conditions. It offers a scalable solution that enhances healthcare by developing digital health products aimed at empowering patients and digitizing healthcare processes. The platform combines an evidence-based clinical approach with elements of behavioral economics and gamification, creating a more engaging healthcare experience. Sidekick's integrated platform supports multi-chronic condition management and personalized care, facilitating connections between users and clinicians while providing valuable data insights. The company collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve health outcomes.

UiPath Inc. develops robotic process automation (RPA) software for enterprises, providing a comprehensive platform designed for hyper automation. This platform enables organizations to identify automation opportunities, build and manage automations, and optimize them at scale. It integrates artificial intelligence to facilitate seamless collaboration between human workers and robots, enhancing operational efficiency. UiPath's solutions cater to a diverse range of industries, including finance, healthcare, manufacturing, and retail, automating various processes such as accounts payable, claims processing, and customer service. Established in 2005 and headquartered in New York, UiPath also offers deployment options in both cloud and on-premise environments, ensuring robust governance and control over automation initiatives.

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

SIRS Therapeutics is a therapeutics company focused on developing pharmaceutical drugs to address acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS). The company has created a fibrin-derived peptide aimed at treating patients suffering from these conditions, which includes those infected with coronavirus. By providing an effective treatment option, SIRS Therapeutics aims to assist healthcare professionals in managing patients with underlying respiratory infections, thereby improving patient outcomes in critical care settings.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Stipe Therapeutics, founded in 2018 and based in Aarhus C, Denmark, develops peptide therapeutics aimed at eliminating tumors and cancer. The company focuses on harnessing the innate immune system to combat cancer by creating first-in-class drugs that target intracellular protein-protein interactions within the STING Pathway. This pathway is a crucial driver of innate immunity and plays a significant role in regulating tumorigenesis and autoimmune disorders. Stipe Therapeutics has successfully identified and validated compounds that sensitize the STING pathway, enabling modulation of the tumor microenvironment to promote a robust anti-tumoral response.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

AMBOSS GmbH is a digital platform based in Cologne, Germany, that caters to the needs of medical students and physicians. Founded in 2012, the company develops and markets a comprehensive medical study platform that offers valuable resources such as study materials and a question bank. The platform is designed to deliver medical knowledge quickly and efficiently, supporting users in their educational and professional endeavors. Originally established as MIAMED GmbH, AMBOSS has positioned itself as a physician-driven resource, enhancing the learning experience for those in the medical field.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

Blackbuck, founded in 2015, is a leading online platform in India that connects shippers with truck operators, transforming the logistics landscape through technology. The company focuses on streamlining the trucking process by facilitating load bookings, offering price discovery, route optimization, and in-transit tracking. This comprehensive approach not only enhances operational efficiency for shippers and truckers but also supports the livelihoods of many individuals within the transportation ecosystem. Blackbuck's commitment to reliability and efficiency has positioned it as the largest trucking network in India, backed by a strong team and notable investors. The company has received multiple accolades, including the 'Young Turks Startup of the Year' award and recognition as 'Company of the Year - Logistics' in 2018. Additionally, Blackbuck's innovative business model has been featured in a Harvard Business School case study.

UiPath Inc. develops robotic process automation (RPA) software for enterprises, providing a comprehensive platform designed for hyper automation. This platform enables organizations to identify automation opportunities, build and manage automations, and optimize them at scale. It integrates artificial intelligence to facilitate seamless collaboration between human workers and robots, enhancing operational efficiency. UiPath's solutions cater to a diverse range of industries, including finance, healthcare, manufacturing, and retail, automating various processes such as accounts payable, claims processing, and customer service. Established in 2005 and headquartered in New York, UiPath also offers deployment options in both cloud and on-premise environments, ensuring robust governance and control over automation initiatives.

Onfido Limited is a provider of automated digital identity verification solutions that utilize artificial intelligence to assess the authenticity of government-issued IDs and compare them with users' facial biometrics. The company's technology is designed to streamline the identity verification process across various applications, including KYC, user onboarding, and fraud detection. Onfido serves a diverse range of sectors, including financial services, gaming, retail, and the sharing economy, helping clients to onboard users more efficiently while mitigating risks associated with identity fraud. Founded in 2010 and headquartered in London, Onfido has expanded its operations with offices in major cities worldwide, including San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Import.io is the number one Web Data Integration provider. Import.io deliver the world’s data directly to enterprises, fueling business insight and competitive advantage. The Import.io Web Data Integration solution extracts, prepares and integrates high-quality comprehensive web data into customers’ analytics platforms and business applications. The company delivers data to more than 850 customers from millions of web sources.

Tonsser is a social network and utility app designed for youth soccer players, allowing them to track their performance statistics and improve their skills. The platform serves as a football talent recognition tool, enabling players to build their football resume and showcase their potential to teammates, coaches, and scouts. By facilitating connections with clubs seeking talent, Tonsser empowers young footballers to enhance their abilities while fostering community engagement and inspiration among peers. Through its features, the app supports players in their development and encourages them to continuously strive for improvement in their game.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

Mapillary AB is an online platform based in Malmö, Sweden, that focuses on street-level imagery and mapping through collaboration and computer vision. Founded in 2013, the company allows users to collect and share photos taken with various cameras, which are then combined to create a comprehensive visual representation of locations around the world. This imagery contributes to improved maps, urban development, and advancements in the automotive industry. Mapillary provides a range of tools, including automated mapping solutions, privacy features, and imagery tagging, to facilitate the collection and utilization of street-level images. With contributions exceeding 500 million images from individuals and organizations globally, Mapillary aims to enhance understanding of diverse locations and make this valuable data accessible to clients and partners such as the World Bank and Toyota Research Institute. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

As the technology leader in organic photovoltaics, Heliatek develops, produces and distributes industrial-grade organic PV solar solutions for virtually any building surface (horizontal, vertical, curved, rigid, and flexible). Heliatek stands for energy solutions designed for various traditional and never been possible before applications based on its unique features – it is ultra-light, flexible and truly green. HeliaSol® is a ready-to-use solution, ideal for retrofitting on existing building structures. HeliaFilm® is tailor-made solar film for companies in the building and construction material industry, to integrate into their façade or roof system products. Heliatek currently employs about 160 people at the Dresden and Ulm locations in Germany. The Free State of Saxony, the Federal Republic of Germany, and the European Union funded research and development, as well as the installation of the production technology.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who has published more than 500 papers related to this technology. glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications. glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications. glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized. glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.

Tonsser is a social network and utility app designed for youth soccer players, allowing them to track their performance statistics and improve their skills. The platform serves as a football talent recognition tool, enabling players to build their football resume and showcase their potential to teammates, coaches, and scouts. By facilitating connections with clubs seeking talent, Tonsser empowers young footballers to enhance their abilities while fostering community engagement and inspiration among peers. Through its features, the app supports players in their development and encourages them to continuously strive for improvement in their game.

Latana Brand Tracking is a provider of cloud-based data technology that revolutionizes the brand tracking process. By utilizing proprietary mobile methodologies, the company focuses on collecting high-quality attitudinal data through millions of micro surveys distributed globally. This system allows for the real-time analysis of consumer attitudes, public opinion, and market trends, thereby offering valuable insights to research agencies, brands, consultancies, public institutions, and academia. Latana aims to eliminate guesswork in brand and marketing strategies, providing reliable data that empowers organizations to make informed decisions and optimize their campaigns, similar to the role Google Analytics plays in other marketing channels.

Dalia is a leading technology that develops cutting-edge research to better understand the needs, desires, and preferences of people around the world. Dalia research’s technology was acquired by PureSpectrum in May of 2022.

glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who has published more than 500 papers related to this technology. glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications. glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications. glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized. glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.

Artfinder is an online marketplace that connects art lovers with independent artists across the globe, facilitating the purchase of authentic and affordable art. With over 10,000 artists and galleries represented, the platform offers a diverse selection of more than 500,000 artworks, including paintings, photography, and sculptures. Artfinder operates with a commitment to social responsibility, being the first Certified B Corporation in the art industry, which emphasizes a balance between purpose and profit. By purchasing art through Artfinder, customers support independent artists in over 100 countries, helping them to sustain their livelihoods through their creative work. The platform has gained significant traction, boasting over 600,000 subscribers worldwide and providing a unique space for individuals to discover and acquire original art for their homes and workplaces.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

As the technology leader in organic photovoltaics, Heliatek develops, produces and distributes industrial-grade organic PV solar solutions for virtually any building surface (horizontal, vertical, curved, rigid, and flexible). Heliatek stands for energy solutions designed for various traditional and never been possible before applications based on its unique features – it is ultra-light, flexible and truly green. HeliaSol® is a ready-to-use solution, ideal for retrofitting on existing building structures. HeliaFilm® is tailor-made solar film for companies in the building and construction material industry, to integrate into their façade or roof system products. Heliatek currently employs about 160 people at the Dresden and Ulm locations in Germany. The Free State of Saxony, the Federal Republic of Germany, and the European Union funded research and development, as well as the installation of the production technology.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx Therapeutics has identified several new targets and examined their mechanisms of action. The company's foundation is built upon the principles of cancer immune-checkpoint therapy, which aims to overcome the resistance mechanisms that tumors utilize to evade immune attacks. These resistance mechanisms often involve specific cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.

Jellynote is an online community platform that serves over 1 million aspiring musicians by providing a comprehensive library of over 400,000 songs, including sheets, tabs, and chords. The platform features original video content such as artist master classes and tutorials, designed to enhance the learning experience for musicians of all skill levels. With its AI-powered technology, Jellynote offers an intuitive edtech solution that includes a game mode for instant feedback and a social mode for connecting musicians. The platform generates revenue through premium subscriptions and advertising, allowing users to engage with music in a collaborative environment. Available on both smartphones and desktops, Jellynote aims to foster connections through music in an increasingly divided world.

Festicket is an online platform that enables music fans to discover and book tickets and travel packages for music festivals worldwide. It provides a comprehensive service that includes festival tickets, accommodation, and travel arrangements, creating a seamless experience for users planning their festival trips. Operating as a two-sided marketplace, Festicket features over 1,000 music festivals across 40 countries and collaborates with a network of 2,000 suppliers to offer a variety of options. The platform also incorporates technology to assist event creators in managing, promoting, and selling their events, facilitating a hassle-free experience for both festival-goers and organizers.

Tonsser is a social network and utility app designed for youth soccer players, allowing them to track their performance statistics and improve their skills. The platform serves as a football talent recognition tool, enabling players to build their football resume and showcase their potential to teammates, coaches, and scouts. By facilitating connections with clubs seeking talent, Tonsser empowers young footballers to enhance their abilities while fostering community engagement and inspiration among peers. Through its features, the app supports players in their development and encourages them to continuously strive for improvement in their game.

EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

Workframe offers a workflow optimization solution specifically designed for the commercial real estate industry. Its web-based software application enables large corporate tenants, landlords, brokers, and service providers to gain enhanced visibility into their workflows. The platform features a visual workflow tool that automates the assignment of critical tasks, streamlines communication, and facilitates collaboration among users. By eliminating time-consuming follow-ups and providing real-time project updates, Workframe empowers businesses to manage risks proactively and drive efficiency, ultimately leading to cost savings across a portfolio of initiatives.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Onfido Limited is a provider of automated digital identity verification solutions that utilize artificial intelligence to assess the authenticity of government-issued IDs and compare them with users' facial biometrics. The company's technology is designed to streamline the identity verification process across various applications, including KYC, user onboarding, and fraud detection. Onfido serves a diverse range of sectors, including financial services, gaming, retail, and the sharing economy, helping clients to onboard users more efficiently while mitigating risks associated with identity fraud. Founded in 2010 and headquartered in London, Onfido has expanded its operations with offices in major cities worldwide, including San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.

Mapillary AB is an online platform based in Malmö, Sweden, that focuses on street-level imagery and mapping through collaboration and computer vision. Founded in 2013, the company allows users to collect and share photos taken with various cameras, which are then combined to create a comprehensive visual representation of locations around the world. This imagery contributes to improved maps, urban development, and advancements in the automotive industry. Mapillary provides a range of tools, including automated mapping solutions, privacy features, and imagery tagging, to facilitate the collection and utilization of street-level images. With contributions exceeding 500 million images from individuals and organizations globally, Mapillary aims to enhance understanding of diverse locations and make this valuable data accessible to clients and partners such as the World Bank and Toyota Research Institute. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Import.io is the number one Web Data Integration provider. Import.io deliver the world’s data directly to enterprises, fueling business insight and competitive advantage. The Import.io Web Data Integration solution extracts, prepares and integrates high-quality comprehensive web data into customers’ analytics platforms and business applications. The company delivers data to more than 850 customers from millions of web sources.

AMBOSS GmbH is a digital platform based in Cologne, Germany, that caters to the needs of medical students and physicians. Founded in 2012, the company develops and markets a comprehensive medical study platform that offers valuable resources such as study materials and a question bank. The platform is designed to deliver medical knowledge quickly and efficiently, supporting users in their educational and professional endeavors. Originally established as MIAMED GmbH, AMBOSS has positioned itself as a physician-driven resource, enhancing the learning experience for those in the medical field.

Zopa is a peer-to-peer lending platform that connects lenders directly with borrowers, eliminating the need for traditional banks as intermediaries. This service allows individuals to invest their savings by lending small amounts to multiple borrowers, thereby spreading risk. Zopa offers an app to help users manage their loans, credit cards, and savings, while also providing tools to monitor their credit scores. The company mitigates risk for lenders through measures such as mandatory monthly direct debit repayments and legal contracts with borrowers. Zopa generates revenue by charging borrowers a fixed fee and a 1% annual fee for lenders. The platform has received several accolades for its innovation and customer service, highlighting its reputation in the financial technology sector.

4SC is a clinical-stage biopharmaceutical company focused on discovering and developing targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases, particularly in areas with significant unmet medical needs. The company aims to offer innovative treatment options that enhance tolerability and efficacy, ultimately improving patients' quality of life. 4SC's drug development pipeline includes two clinical candidates, resminostat and Domatinostat, which are protected by a strong portfolio of patents. The company operates primarily in Germany and the European Union, while also generating revenue from various other countries.

Soundtrack Your Brand is a business-to-business music platform that allows small business owners to create and legally play tailored playlists in their venues. The platform offers a subscription-based service that grants access to a commercial catalog of songs, enabling businesses to play any music they choose without legal concerns. This service helps businesses enhance their digital media presence by curating playlists that suit various settings and events, ensuring a positive experience for both customers and employees. Soundtrack Your Brand aims to simplify the process of music selection for businesses, providing unlimited and customizable playlists during operational hours.

Latana Brand Tracking is a provider of cloud-based data technology that revolutionizes the brand tracking process. By utilizing proprietary mobile methodologies, the company focuses on collecting high-quality attitudinal data through millions of micro surveys distributed globally. This system allows for the real-time analysis of consumer attitudes, public opinion, and market trends, thereby offering valuable insights to research agencies, brands, consultancies, public institutions, and academia. Latana aims to eliminate guesswork in brand and marketing strategies, providing reliable data that empowers organizations to make informed decisions and optimize their campaigns, similar to the role Google Analytics plays in other marketing channels.

Dalia is a leading technology that develops cutting-edge research to better understand the needs, desires, and preferences of people around the world. Dalia research’s technology was acquired by PureSpectrum in May of 2022.

EyeEm is a photography company that operates a photo-sharing platform aimed at connecting a global creative community with iconic brands. The platform features a collection of over 90 million images contributed by more than 20 million photographers worldwide. Through its smartphone application, EyeEm allows users to preview, purchase, and share imagery, thereby enhancing visibility and opportunities for both photographers and brands. The company's focus on computer vision technology further supports its mission to facilitate meaningful connections within the creative industry.

Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.

Onfido Limited is a provider of automated digital identity verification solutions that utilize artificial intelligence to assess the authenticity of government-issued IDs and compare them with users' facial biometrics. The company's technology is designed to streamline the identity verification process across various applications, including KYC, user onboarding, and fraud detection. Onfido serves a diverse range of sectors, including financial services, gaming, retail, and the sharing economy, helping clients to onboard users more efficiently while mitigating risks associated with identity fraud. Founded in 2010 and headquartered in London, Onfido has expanded its operations with offices in major cities worldwide, including San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.

Mapillary AB is an online platform based in Malmö, Sweden, that focuses on street-level imagery and mapping through collaboration and computer vision. Founded in 2013, the company allows users to collect and share photos taken with various cameras, which are then combined to create a comprehensive visual representation of locations around the world. This imagery contributes to improved maps, urban development, and advancements in the automotive industry. Mapillary provides a range of tools, including automated mapping solutions, privacy features, and imagery tagging, to facilitate the collection and utilization of street-level images. With contributions exceeding 500 million images from individuals and organizations globally, Mapillary aims to enhance understanding of diverse locations and make this valuable data accessible to clients and partners such as the World Bank and Toyota Research Institute. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Hintsa is a leading coaching company that focuses on evidence-based methods to support athletes and business professionals in achieving sustainable success. The company employs scientifically-driven approaches that have been tested in high-pressure environments, including sports and corporate settings. Hintsa's clientele includes Formula 1 champions, executives from Fortune 500 companies, consultants, and professionals in various fields such as healthcare and energy. By emphasizing both performance enhancement and well-being, Hintsa aims to help clients lead healthier, more balanced lives while excelling in their respective domains. The company is recognized as a thought leader in coaching, drawing attention from influential organizations such as the World Economic Forum and McKinsey Quarterly.

YPlan uncovers the best events every day so you can get out and Live Your City. Get the lowdown on cool dates, hidden culture and where to hang with friends. Discover, book, go – it's that simple. Flash your YPlan ticket and you're in. Founded in London in February, 2012, YPlan works directly with 3500+ event partners worldwide, has over 1.5 million users, and 1000+ 5* reviews on App Store.